Safety & Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

See also
Status	Clinical Trial	Phase
Completed	`NCT01434680` - Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers	Phase 2
Completed	`NCT01424644` - A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents	Phase 4
Completed	`NCT00384397` - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers	Phase 3
Completed	`NCT01453348` - Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine	Phase 3
Completed	`NCT01214837` - Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life	Phase 3
Completed	`NCT00874549` - Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years	Phase 1/Phase 2
Completed	`NCT00355121` - Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®	Phase 2
Completed	`NCT02591290` - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects	Phase 4
Completed	`NCT01717638` - Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1	Phase 3
Completed	`NCT01482052` - Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis	Phase 1
Completed	`NCT01466387` - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults	Phase 3
Completed	`NCT01239043` - Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination	Phase 2
Completed	`NCT00994695` - Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine	Phase 2
Completed	`NCT01732627` - Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older	Phase 2
Completed	`NCT01478347` - A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults	Phase 3
Completed	`NCT00483574` - Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers	Phase 3
Completed	`NCT00474487` - A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults	Phase 3
Completed	`NCT03205358` - Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers	Phase 2
Not yet recruiting	`NCT06226714` - A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds	Phase 3
Completed	`NCT00667602` - Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers	Phase 3

NCT number	NCT00310817
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	March 2005
Completion date	May 2006

Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms